The emergence of compounds like copyright and Semaglutide signifies a significant shift in how we treat blood sugar. These new therapies belong to a class known as GLP-1 target agonists, which duplicate the effects of a natural hormone that controls sugar levels and appetite. Initially, developed for diabetes, their effectiveness in supporting fat